Efficacy is more like MTX but I think the higher infection and discontinuation seen with apremilast in this 16 weeks trial is the bigger problem as this should be worse over longer period of use.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.